129 related articles for article (PubMed ID: 31788130)
1. A combination of inhibitors of glycolysis, glutaminolysis and
Schcolnik-Cabrera A; Dominguez-Gómez G; Chávez-Blanco A; Ramírez-Yautentzi M; Morales-Bárcenas R; Chávez-Díaz J; Taja-Chayeb L; Dueáas-González A
Oncol Lett; 2019 Dec; 18(6):6909-6916. PubMed ID: 31788130
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and antitumor efficacy
Cervantes-Madrid D; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
Oncol Lett; 2017 Mar; 13(3):1905-1910. PubMed ID: 28454342
[TBL] [Abstract][Full Text] [Related]
3. The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.
Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Lai D; Hua S; Tovar AR; Diaz-Chavez J; Duenas-Gonzalez A
Oncol Lett; 2020 Sep; 20(3):3053-3060. PubMed ID: 32782623
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.
Cervantes-Madrid D; Dueñas-González A
Oncol Rep; 2015 Sep; 34(3):1533-42. PubMed ID: 26134042
[TBL] [Abstract][Full Text] [Related]
5. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
6. Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer.
Schcolnik-Cabrera A; Dueñas-Gonzalez A
Methods Mol Biol; 2021; 2174():45-69. PubMed ID: 32813244
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.
Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Vargas-Castillo A; Ponce-Toledo RI; Lai D; Hua S; Tovar AR; Torres N; Perez-Montiel D; Diaz-Chavez J; Duenas-Gonzalez A
Sci Rep; 2021 Mar; 11(1):5222. PubMed ID: 33664364
[TBL] [Abstract][Full Text] [Related]
9. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
10. Aqueous extract of Vitex trifolia L. (Labiatae) inhibits LPS-dependent regulation of inflammatory mediators in RAW 264.7 macrophages through inhibition of Nuclear Factor kappa B translocation and expression.
Matsui M; Adib-Conquy M; Coste A; Kumar-Roiné S; Pipy B; Laurent D; Pauillac S
J Ethnopharmacol; 2012 Aug; 143(1):24-32. PubMed ID: 22732725
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
12. Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
Meijer TWH; Peeters WJM; Dubois LJ; van Gisbergen MW; Biemans R; Venhuizen JH; Span PN; Bussink J
Lung Cancer; 2018 Dec; 126():32-40. PubMed ID: 30527190
[TBL] [Abstract][Full Text] [Related]
13. Erratum: A combination of inhibitors of glycolysis, glutaminolysis and
Schcolnik-Cabrera A; Dominguez-Gómez G; Chávez-Blanco A; Ramírez-Yautentzi M; Morales-Bárcenas R; Díaz-Chávez J; Taja-Chayeb L; Dueñas-González A
Oncol Lett; 2020 Mar; 19(3):2071. PubMed ID: 32194704
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.
Cioccoloni G; Aquino A; Notarnicola M; Caruso MG; Bonmassar E; Zonfrillo M; Caporali S; Faraoni I; Villivà C; Fuggetta MP; Franzese O
J Chemother; 2020 Feb; 32(1):30-40. PubMed ID: 31775585
[TBL] [Abstract][Full Text] [Related]
15. Study on the mechanism of oral administration of tetrandrine during neoadjuvant chemotherapy for colon cancer.
Li D; Li J; Yu F; Wang B; Liu B
Oncol Lett; 2023 Jun; 25(6):225. PubMed ID: 37153045
[TBL] [Abstract][Full Text] [Related]
16. STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells.
Li M; Jin R; Wang W; Zhang T; Sang J; Li N; Han Q; Zhao W; Li C; Liu Z
Oncotarget; 2017 Apr; 8(15):24777-24784. PubMed ID: 28445971
[TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NF-kappaB activation and chemokine expression by the leukocyte glycoprotein, CD43, in colon cancer cells.
Laos S; Baeckström D; Hansson GC
Int J Oncol; 2006 Mar; 28(3):695-704. PubMed ID: 16465375
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules.
Kant S; Kumar A; Singh SM
Biochim Biophys Acta; 2012 Nov; 1820(11):1764-73. PubMed ID: 22877747
[TBL] [Abstract][Full Text] [Related]
20. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.
Olsnes AM; Ersvaer E; Ryningen A; Paulsen K; Hampson P; Lord JM; Gjertsen BT; Kristoffersen EK; Bruserud Ø
Br J Haematol; 2009 Jun; 145(6):761-74. PubMed ID: 19388934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
